share_log

BTIG Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $16

Benzinga ·  Jul 25, 2023 04:32

BTIG analyst Justin Zelin initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment